Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 28, 2021 12:04 ET | Source: Quantum Genomics

Quantum Genomics Secures €3 Million Non-dilutive Financing

€1.5 million guaranteed by the French government (PGE) and granted by BNP bank €1.5 million innovation and R&D loan granted by Bpifrance Funding will allow for acceleration of R&D programs ...
April 21, 2021 02:00 ET | Source: Quantum Genomics

Quantum Genomics Will Present Top-line Results From its QUORUM Study of Firibastat in Heart Failure Post Myocardial Infarction at the European Society of Cardiology (ESC) Meeting

PARIS, April 21, 2021 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the...
April 20, 2021 02:00 ET | Source: Quantum Genomics

Quantum Genomics Announces the End of its Collaboration with Qilu for the Development and Commercialization of Firibastat in China

PARIS and NEW YORK, April 20, 2021 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that...
March 25, 2021 13:00 ET | Source: Quantum Genomics

Quantum Genomics Reports Full Year 2020 Operating and Financial Results

Recruitment of first subjects for Phase III trial in difficult-to-treat and resistant arterial hypertension patients Finalization of recruitment for Phase IIb trial in heart failure with upcoming...
February 09, 2021 12:00 ET | Source: Quantum Genomics

Orient EuroPharma Acquires Equity Stake in Quantum Genomics

PARIS and NEW YORK, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new class of drugs...
January 18, 2021 15:30 ET | Source: Quantum Genomics

Quantum Genomics Launches Phase III Pivotal REFRESH Study in Difficult-to-treat/Resistant Hypertension with Once-a-day Formulation of Firibastat

PARIS and NEW YORK, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly...
December 16, 2020 02:00 ET | Source: Quantum Genomics

Quantum Genomics Signs a Strategic Contract with Delpharm

PARIS and NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new class of drugs...
December 15, 2020 02:00 ET | Source: Quantum Genomics

Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Faran

Quantum Genomics to receive up to $12.1 million in upfront and milestone payments plus double-digit royalties on sales Faran to receive an exclusive license to develop and commercialize firibastat...
December 02, 2020 11:50 ET | Source: Quantum Genomics

Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with DongWha Pharm

Quantum Genomics to receive up to $18.5 million in upfront and milestone payments plus double-digit royalties on sales DongWha Pharm to receive an exclusive license to develop and commercialize...
November 02, 2020 12:00 ET | Source: Quantum Genomics

Quantum Genomics Announces End of Financing Agreement with Negma Group Ltd/Park Partners

PARIS and NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly...